Abstract
The introduction of long-acting beta agonists (LABAs) was considered a major advance in bronchodilator therapy with evidence that their use led to improved lung function and quality of life. However, the use of LABAs has raised safety concerns, such as their potential to provoke severe asthma exacerbations (SAEs) and death. This systematic review of major findings discusses the safety controversy surrounding LABA therapy and provides background for the U.S. Food and Drug Administrations warnings concerning LABA use. Findings from large clinical trials and several meta-analyses are described and compared in terms of their implications for the safety of LABAs. Monotherapy LABA therapy in the treatment of asthma remains controversial and is not recommended by the most recent asthma management guidelines. Despite the existence of numerous published studies, we conclude that more well-designed research on this topic --- to determine whether LABAs are associated with SAEs, such as asthma-related hospitalizations, intubations, and emergency room visits, or death --- is required. Particularly needed is research that makes use of large, secondary longitudinal databases.
Keywords: Long-acting beta agonists (LABAs), asthma, SMART trial, safety controversy, African Americans, pediatric LABA use
Current Drug Safety
Title: Evaluating Safety of Long-Acting Beta Agonists (LABAs) in Patients with Asthma
Volume: 5 Issue: 3
Author(s): Boyang Bian, Christina M.L. Kelton, Patricia R. Wigle and Jeff J. Guo
Affiliation:
Keywords: Long-acting beta agonists (LABAs), asthma, SMART trial, safety controversy, African Americans, pediatric LABA use
Abstract: The introduction of long-acting beta agonists (LABAs) was considered a major advance in bronchodilator therapy with evidence that their use led to improved lung function and quality of life. However, the use of LABAs has raised safety concerns, such as their potential to provoke severe asthma exacerbations (SAEs) and death. This systematic review of major findings discusses the safety controversy surrounding LABA therapy and provides background for the U.S. Food and Drug Administrations warnings concerning LABA use. Findings from large clinical trials and several meta-analyses are described and compared in terms of their implications for the safety of LABAs. Monotherapy LABA therapy in the treatment of asthma remains controversial and is not recommended by the most recent asthma management guidelines. Despite the existence of numerous published studies, we conclude that more well-designed research on this topic --- to determine whether LABAs are associated with SAEs, such as asthma-related hospitalizations, intubations, and emergency room visits, or death --- is required. Particularly needed is research that makes use of large, secondary longitudinal databases.
Export Options
About this article
Cite this article as:
Bian Boyang, M.L. Kelton Christina, R. Wigle Patricia and J. Guo Jeff, Evaluating Safety of Long-Acting Beta Agonists (LABAs) in Patients with Asthma, Current Drug Safety 2010; 5 (3) . https://dx.doi.org/10.2174/157488610791698316
DOI https://dx.doi.org/10.2174/157488610791698316 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Extraction, Structure and Bioactivities of the Polysaccharides from Fructus corni
Recent Patents on Food, Nutrition & Agriculture Seminal Fluid Hypersensitivity: A Case Report and Review of the Literature
Current Women`s Health Reviews Medicinal Perspective of Indole Derivatives: Recent Developments and Structure-Activity Relationship Studies
Current Drug Targets Systems Biology Approaches and Metabolomics for Understanding Japanese Traditional Kampo Medicine
Current Pharmacogenomics and Personalized Medicine Treatment of Takotsubo Cardiomyopathy
Current Pharmaceutical Design Herbal Highs: Review on Psychoactive Effects and Neuropharmacology
Current Neuropharmacology Pathophysiology of IgG4-Related Disease
Current Immunology Reviews (Discontinued) Systemic Approach to the Study of Complex Bone Disorders at the Whole- Genome Level
Current Genomics Adherence in Asthma
Current Respiratory Medicine Reviews Recent Progress in Rational Drug Design of Neuraminidase Inhibitors
Current Medicinal Chemistry Resistance to Aspirin and Thienopyridines in Diabetes Mellitus and Metabolic Syndrome
Current Vascular Pharmacology Simultaneous Analysis of Ipratropium Bromide and its Related Substances Using HPLC
Current Pharmaceutical Analysis Chronopharmaceutics: A Promising Drug Delivery Finding of the Last Two Decades
Recent Patents on Drug Delivery & Formulation Refractory Cough as a Remote Manifestation of Retroperitoneal Liposarcoma
Current Cancer Therapy Reviews Hepatoprotective Effects of Resveratrol in Non-Alcoholic Fatty Live Disease
Current Pharmaceutical Design Cyclodextrin Based Nanosponges: A Multidimensional Drug Delivery System and its Biomedical Applications
Current Drug Delivery Perspective on Nanoparticle Technology for Biomedical Use
Current Pharmaceutical Design MIF and the Genetic Basis of Macrophage Responsiveness
Current Immunology Reviews (Discontinued) Eosinophils in Cancer: Favourable or Unfavourable?
Current Medicinal Chemistry Signal Transduction Therapy with Rationally Designed Kinase Inhibitors
Current Signal Transduction Therapy